About DC Bead

Important Product Information

DC Bead Indications:

  • DC Bead™ is CE marked and is indicated for the treatment of malignant hypervascular tumours and loading with doxorubicin drug
  • DC Bead™ is also indicated for loading with irinotecan for the treatment of metastatic colorectal cancer (mCRC).  Both indications may not be available in your territory


  • Embolisation with DC Bead™ should only be performed by a physician with appropriate interventional occlusion training in the region intended to be embolised
  • Exceeding a loading dose of 37.5mg doxorubicin per 1ml DC Bead™ may lead to some systemic distribution of doxorubicin and related side effect

Potential Complications:

  1. Undesirable reflux or passage of DC Bead™ into normal arteries adjacent to the targeted lesion or through the lesion into other arteries or arterial beds
  2. Non-target embolization
  3. Pulmonary embolization
  4. Ischemia at an undesirable location
  5. Capillary bed saturation and tissue damage
  6. Ischemic stroke or ischemic infarction
  7. Vessel or lesion rupture and haemorrhage
  8. Neurological deficits including cranial nerve palsies
  9. Vasospasm
  10. Death
  11. Recanalisation
  12. Foreign body reactions necessitating medical intervention
  13. Infection necessitating medical intervention

DC Bead™ and/or all indications may not be available in your territory. DC Bead™ is not currently cleared by the FDA for sale or distribution in the USA.

DC Bead is a trademark of Biocompatibles UK Ltd and DC Bead is a registered trademark in China, EU, Japan, Republic of Korea and US.

DC Bead is an embolic Drug-Eluting Bead capable of loading and releasing in a controlled
manner chemotherapeutic agents. DC Bead is used in trans-arterial chemoembolisation
(TACE). This is a minimally invasive (non-surgical) procedure performed by an interventional